Search research articles
Contact Us
Filters
Showing results (11-20 of 40) with videos related to
Page
of 4
Sort By:
Biorxiv : the Preprint Server for Biology
|
January 27, 2025
Matrix stiffness modulated release of spheroid-derived extracellular vesicles and discovery of Piezo1 cargo
Maulee Sheth, Manju Sharma, Supasek Kongsomros, et al.
Science Signaling
|
April 26, 2018
A defect in KCa3.1 channel activity limits the ability of CD8<sup>+</sup> T cells from cancer patients to infiltrate an adenosine-rich microenvironment
Ameet A Chimote, Andras Balajthy, Michael J Arnold, et al.
Oncotarget
|
November 16, 2017
Comprehensive microRNA-sequencing of exosomes derived from head and neck carcinoma cells <i>in vitro</i> reveals common secretion profiles and potential utility as salivary biomarkers
Scott Langevin, Damaris Kuhnell, Tess Parry, et al.
World Neurosurgery
|
June 20, 2024
Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review
Joel Kaye, John Na, Shravan Atluri, et al.
Journal for Immunotherapy of Cancer
|
March 29, 2020
CD244 represents a new therapeutic target in head and neck squamous cell carcinoma
Laura Agresta, Maria Lehn, Kristin Lampe, et al.
Journal of the American College of Surgeons
|
April 23, 2024
Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy
Sourat Darabi, Tolulope Adeyelu, Andrew Elliott, et al.
Oral Oncology
|
January 9, 2019
High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma
Sulsal Haque, Vidhya Karivedu, Muhammed K Riaz, et al.
British Journal of Haematology
|
April 3, 2019
Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013
Vincent Ribrag, David E Avigan, Damian J Green, et al.
Journal of Neurology
|
December 4, 2025
Neurological immune-related adverse events of immune checkpoint inhibitors: clinical and hematological risk factors
Luca Marsili, Jesus Abanto, Samuel B Marcucci, et al.
American Journal of Cancer Research
|
March 14, 2025
Early-phase clinical trials in the pandemic era: a four-year experience from an academic cancer center
Katie Moreland, Bethany Fuhrman, Kayla Webb, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 40) with videos related to
Sort By:
Page
of 4
Biorxiv : the Preprint Server for Biology
|
January 27, 2025
Matrix stiffness modulated release of spheroid-derived extracellular vesicles and discovery of Piezo1 cargo
Maulee Sheth, Manju Sharma, Supasek Kongsomros, et al.
Science Signaling
|
April 26, 2018
A defect in KCa3.1 channel activity limits the ability of CD8<sup>+</sup> T cells from cancer patients to infiltrate an adenosine-rich microenvironment
Ameet A Chimote, Andras Balajthy, Michael J Arnold, et al.
Oncotarget
|
November 16, 2017
Comprehensive microRNA-sequencing of exosomes derived from head and neck carcinoma cells <i>in vitro</i> reveals common secretion profiles and potential utility as salivary biomarkers
Scott Langevin, Damaris Kuhnell, Tess Parry, et al.
World Neurosurgery
|
June 20, 2024
Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review
Joel Kaye, John Na, Shravan Atluri, et al.
Journal for Immunotherapy of Cancer
|
March 29, 2020
CD244 represents a new therapeutic target in head and neck squamous cell carcinoma
Laura Agresta, Maria Lehn, Kristin Lampe, et al.
Journal of the American College of Surgeons
|
April 23, 2024
Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy
Sourat Darabi, Tolulope Adeyelu, Andrew Elliott, et al.
Oral Oncology
|
January 9, 2019
High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma
Sulsal Haque, Vidhya Karivedu, Muhammed K Riaz, et al.
British Journal of Haematology
|
April 3, 2019
Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013
Vincent Ribrag, David E Avigan, Damian J Green, et al.
Journal of Neurology
|
December 4, 2025
Neurological immune-related adverse events of immune checkpoint inhibitors: clinical and hematological risk factors
Luca Marsili, Jesus Abanto, Samuel B Marcucci, et al.
American Journal of Cancer Research
|
March 14, 2025
Early-phase clinical trials in the pandemic era: a four-year experience from an academic cancer center
Katie Moreland, Bethany Fuhrman, Kayla Webb, et al.
Page
of 4